For cancer therapies to succeed, induction of an anticancer immune response is required. Immuno-oncology approaches are shaping the treatment landscape for patients with advanced-stage melanoma and other solid tumours. These new approaches may enhance immune system activity to improve outcomes, including the potential to achieve long-term survival benefits in many patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Robert, C., Soria, J. C. & Eggermont, A. M. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur. J. Cancer 49, 2968–2971 (2013).
Schadendorf, D. et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma [abstract]. Eur. J. Cancer 49, LBA24 (2013).
Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
Hamid, O. et al. Safety and tumour responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369, 134–144 (2013).
Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133 (2013).
Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694–1703 (2012).
Ribas, A., Hodi, F. S., Callahan, M., Konto, C. & Wolchok, J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368, 1365–1366 (2013).
Kroemer, G., Galluzzi, L., Kepp, O. & Zitvogel, L. Immunogenic cell death in cancer therapy. Ann. Rev. Immunol. 31, 51–72 (2013).
Postow, M. A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925–931 (2012).
Acknowledgements
The authors take full responsibility for the content of this publication, and confirm that it reflects their viewpoint and medical expertise. StemScientific, funded by Bristol-Myers Squibb, provided writing and editing support. Bristol-Myers Squibb did not influence the content of the manuscript, nor did the authors receive financial compensation for authoring the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.M.M.E. has participated in advisory boards for Amgen, Bristol-Myers Squibb, GlaxoSmithKline, MedImmune, MSD; C.R. has participated in advisory boards for Amgen, Cellgene, Bristol-Myers Squibb, GlaxoSmithKline, MSD, Novartis, Roche.
Rights and permissions
About this article
Cite this article
Eggermont, A., Robert, C. Smart therapeutic strategies in immuno-oncology. Nat Rev Clin Oncol 11, 181–182 (2014). https://doi.org/10.1038/nrclinonc.2014.36
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.36
This article is cited by
-
Compound 13, an α1-selective small molecule activator of AMPK, potently inhibits melanoma cell proliferation
Tumor Biology (2016)
-
Curdlan-Conjugated PLGA Nanoparticles Possess Macrophage Stimulant Activity and Drug Delivery Capabilities
Pharmaceutical Research (2015)
-
Clinical cancer research: the past, present and the future
Nature Reviews Clinical Oncology (2014)
